Combined Anabolic Therapy
Massachusetts General Hospitaln = 503 Feb 2025 to est. 19 Nov 2027
Osteoporosis, Postmenopausal · Osteoporosis
PepBank has 484 teriparatide studies with results. 430 of them gave teriparatide, with 2,709 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 2,709 results and 1,327 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Teriparatide matches residues 1 to 34 of mature human parathyroid hormone. It is a PTH1 receptor agonist. It differs from intact PTH and long-acting PTH prodrugs. The sequence is a natural fragment, irrespective of manufacturing method.
| Target | Action | Evidence |
|---|---|---|
| Parathyroid hormone 1 receptorPTH1RQ03431 (opens in a new tab) | Agonist | IUPHAR/BPS curated receptor assay dataSource (opens in a new tab) |
| Parathyroid hormone 2 receptorPTH2RP49190 (opens in a new tab) | Agonist | IUPHAR/BPS curated receptor assay dataSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
34 amino acids
No sequence is listed for the parent, so no alignment is shown.The 34-residue sequence matches UniProt P01270 residues 32-65 and mature hormone residues 1-34. This record does not link a parent seed record.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 9.44 · Net charge at pH 7.4: 1.28
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 9.00 |
| 1 | 8.99 |
| 2 | 8.94 |
| 3 | 8.47 |
| 4 | 6.39 |
| 5 | 4.36 |
| 6 | 3.33 |
| 7 | 1.70 |
| 8 | 0.89 |
| 9 | 0.25 |
| 10 | −0.38 |
| 11 | −1.90 |
| 12 | −3.30 |
| 13 | −4.50 |
| 14 | −4.94 |
34 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
Teriparatide (PTH 1-34) has 34 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.
SMILES fromPubChem CID 16133850(opens in a new tab)
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NAn ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | S | 0° | -0.18 |
| 2 | V | 100° | 1.08 |
| 3 | S | 200° | -0.18 |
| 4 | E | 300° | -0.74 |
| 5 | I | 40° | 1.38 |
| 6 | Q | 140° | -0.85 |
| 7 | L | 240° | 1.06 |
| 8 | M | 340° | 0.64 |
| 9 | H | 80° | -0.40 |
| 10 | N | 180° | -0.78 |
| 11 | L | 280° | 1.06 |
| 12 | G | 20° | 0.48 |
| 13 | K | 120° | -1.50 |
| 14 | H | 220° | -0.40 |
| 15 | L | 320° | 1.06 |
| 16 | N | 60° | -0.78 |
| 17 | S | 160° | -0.18 |
| 18 | M | 260° | 0.64 |
| 19 | E | 0° | -0.74 |
| 20 | R | 100° | -2.53 |
| 21 | V | 200° | 1.08 |
| 22 | E | 300° | -0.74 |
| 23 | W | 40° | 0.81 |
| 24 | L | 140° | 1.06 |
| 25 | R | 240° | -2.53 |
| 26 | K | 340° | -1.50 |
| 27 | K | 80° | -1.50 |
| 28 | L | 180° | 1.06 |
| 29 | Q | 280° | -0.85 |
| 30 | D | 20° | -0.90 |
| 31 | V | 120° | 1.08 |
| 32 | H | 220° | -0.40 |
| 33 | N | 320° | -0.78 |
| 34 | F | 60° | 1.19 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
484 of 1,327 studies have results (36%), published 1981 to 2026. Top row: every study. Bottom row: studies with results about Teriparatide (PTH 1-34), by class. The rows use different scales.
Studies1,326 in all, 1974 to 2026
Studies with results484 in all, 1981 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
168 trials match. Highest phase first. Data from ClinicalTrials.gov.
25 of 168 trials
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01750086Jan 2013 to Aug 2014
25 trials · 5 ongoing · 15 completed · 11 with posted results · source ClinicalTrials.gov (opens in a new tab)
Massachusetts General Hospitaln = 503 Feb 2025 to est. 19 Nov 2027
Osteoporosis, Postmenopausal · Osteoporosis
VA Office of Research and Developmentn = 401 Jul 2019 to 30 Jun 2025
Male Osteoporosis
University of Edinburghn = 3501 Nov 2016 to 21 Mar 2025
Osteogenesis Imperfecta
Sheffield Teaching Hospitals NHS Foundation Trustn = 19Jan 2011 to Aug 2015
Osteoporosis
Madhumathi Raon = 6021 Mar 2022 to est. 31 Jan 2027
Age-Related Osteoporosis
Paul F Netzeln = 401 Feb 2024 to est. 31 Dec 2029
Osteoporosis
Ditte Hansenn = 4815 Dec 2021 to est. 1 Sept 2027
Adynamic Bone Disease · Chronic Kidney Diseases · Cardiac Disease · Chronic Kidney Disease-Mineral and Bone Disorder
Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024
Bone Regeneration
Massachusetts General Hospitaln = 372 Sept 2019 to 18 Apr 2022
Postmenopausal Osteoporosis
University of South Carolinan = 1838 Dec 2022 to est. 30 Dec 2026
Stress Fracture of Tibia or Fibula
Medical University of Viennan = 261 Mar 2017 to 30 Sept 2022
Postmenopausal Osteoporosis · Diabetes Type 2
Shane Burchn = 36Aug 2011 to Dec 2016
Lumbar Spondylosis · Lumbar Spondylolisthesis · Adult Degenerative Lumbar Scoliosis
Massachusetts General Hospitaln = 76Aug 2014 to Feb 2020
Postmenopausal Osteoporosis
Shinshu Universityn = 100May 2014 to est. Nov 2022
Osteoporosis
Seoul National University Bundang Hospitaln = 641 Jan 2014 to est. 31 Dec 2020
Spine Deformity
Eli Lilly and Companyn = 224Apr 2009 to Aug 2015
Osteoporosis
Eli Lilly and Companyn = 1,366Oct 2012 to Jul 2016
Postmenopausal Osteoporosis
Oregon Health and Science Universityn = 79Jun 2005 to Jan 2011
Osteogenesis Imperfecta
University Hospital, Linkoepingn = 34Aug 2012 to 1 Jan 2019
Spinal Stenosis
Susan L. Greenspann = 13Dec 2012 to Sept 2016
Osteoporosis · Atypical Femoral Fracture
Health Research, Inc.n = 60Aug 2013 to est. Aug 2018
Osteoporosis
University of Pennsylvanian = 33Jul 2008 to Dec 2012
Osteoporosis, Osteopenia
Brigham and Women's Hospitaln = 26Aug 2011 to 28 Jul 2016
Rheumatoid Arthritis
Massachusetts General Hospitaln = 27Jan 2013 to Aug 2014
Postmenopausal Osteoporosis
Nottingham University Hospitals NHS Trustn = 10Oct 2016 to est. Oct 2017
Fracture, Ankle
30 more mention it but do not test it. They are not trials of Teriparatide (PTH 1-34): they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
1,327 studies match. Retracted studies are left out.
Showing 25 of 1,327 studiesquery qry_ca79827be550cd6775f0aa23
484 studies in all, 23 on this page
Randomized controlled trial · 2001
Neer et al. 2001The New England journal of medicinecited by 3,051
PMID 11346808DOI 10.1056/nejm200105103441904PUB-11346808
Randomized controlled trial · 2007
Saag et al. 2007The New England journal of medicinen = 428cited by 569
PMID 18003959DOI 10.1056/nejmoa071408PUB-18003959
Randomized controlled trial · 2003
Orwoll et al. 2003Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 454
PMID 12510800DOI 10.1359/jbmr.2003.18.1.9PUB-12510800
Animal study (in vivo) · rat · 2002
Vahle et al. 2002Toxicologic pathologyn = 60cited by 447
PMID 12051548DOI 10.1080/01926230252929882PUB-12051548
Not a test of Teriparatide (PTH 1-34) alone · 2015
Leder et al. 2015Lancet (London, England)cited by 426
PMID 26144908PMC4620731DOI 10.1016/s0140-6736(15)61120-5PUB-26144908
Non-randomized trial · 2003
Jiang et al. 2003Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchn = 51cited by 414
PMID 14606504DOI 10.1359/jbmr.2003.18.11.1932PUB-14606504
Randomized controlled trial · 2010
Aspenberg et al. 2010Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchn = 68cited by 368
PMID 19594305DOI 10.1359/jbmr.090731PUB-19594305
Randomized controlled trial · 2017
Langdahl et al. 2017Lancet (London, England)n = 432cited by 360
PMID 28755782DOI 10.1016/s0140-6736(17)31613-6PUB-28755782
Randomized controlled trial · 2013
Tsai et al. 2013Lancet (London, England)cited by 335
PMID 23683600PMC4083737DOI 10.1016/s0140-6736(13)60856-9PUB-23683600
Non-randomized trial · 2004
Ettinger et al. 2004Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 319
PMID 15068497DOI 10.1359/jbmr.040117PUB-15068497
Randomized controlled trial · 2009
Saag et al. 2009Arthritis and rheumatismn = 428cited by 298
PMID 19877063DOI 10.1002/art.24879PUB-19877063
Animal study (in vivo) · rat · 2004
Vahle et al. 2004Toxicologic pathologycited by 253
PMID 15204966DOI 10.1080/01926230490462138PUB-15204966
Animal study (in vivo) · rat · 1999
Andreassen et al. 1999Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 247
PMID 10352105DOI 10.1359/jbmr.1999.14.6.960PUB-10352105
Randomized controlled trial · 2011
Cosman et al. 2011Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 246
PMID 20814967DOI 10.1002/jbmr.238PUB-20814967
Randomized controlled trial · 2002
Body et al. 2002The Journal of clinical endocrinology and metabolismn = 146cited by 239
PMID 12364430DOI 10.1210/jc.2002-020334PUB-12364430
Animal study (in vivo) · rat · 2005
Alkhiary et al. 2005The Journal of bone and joint surgery. American volumecited by 228
PMID 15805200DOI 10.2106/jbjs.d.02115PUB-15805200
Non-randomized trial · 2013
Ohtori et al. 2013Spinen = 42cited by 219
PMID 23354115DOI 10.1097/brs.0b013e31828826ddPUB-23354115
Not a test of Teriparatide (PTH 1-34) alone · 2005
Chen et al. 2005Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 216
PMID 15883636DOI 10.1359/jbmr.050105PUB-15883636
Randomized controlled trial · 2012
Nakamura et al. 2012The Journal of clinical endocrinology and metabolismn = 578cited by 204
PMID 22723322DOI 10.1210/jc.2011-3479PUB-22723322
Randomized controlled trial · 2004
Lindsay et al. 2004Archives of internal medicinecited by 202
PMID 15477438DOI 10.1001/archinte.164.18.2024PUB-15477438
Observational study · 2008
Obermayer-Pietsch et al. 2008Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchn = 503cited by 202
PMID 18505369DOI 10.1359/jbmr.080506PUB-18505369
Non-randomized trial · 2006
Lindsay et al. 2006Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 199
PMID 16491283DOI 10.1359/jbmr.051109PUB-16491283
Animal study (in vivo) · rat · 2002
Nakajima et al. 2002Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 198
PMID 12412812DOI 10.1359/jbmr.2002.17.11.2038PUB-12412812
829 studies in all, 2 on this page
PubMed tag: Randomized Controlled Trial, Multicenter Study · 2018
Kendler et al. 2018Lancet (London, England)cited by 422
PMID 29129436DOI 10.1016/s0140-6736(17)32137-2PUB-29129436
PubMed tag: Randomized Controlled Trial, Clinical Trial · 2005
McClung et al. 2005Archives of internal medicinecited by 316
PMID 16087825DOI 10.1001/archinte.165.15.1762PUB-16087825
Page 1 of 10
Nakamura T · The Journal of clinical endocrinology and metabolism · 2012
Randomized controlled trial · 6 results
Li M · Archives of osteoporosis · 2022
Randomized controlled trial · 8 results
Sugimoto T · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
Randomized controlled trial · 4 results
Langdahl BL · Lancet (London, England) · 2017
Randomized controlled trial · 7 results
Saag KG · The New England journal of medicine · 2007
Randomized controlled trial · 5 results
Langdahl BL · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2009
Randomized controlled trial · 10 results
Hagino H · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
Randomized controlled trial · 6 results
Tanaka I · Journal of bone and mineral metabolism · 2021
Randomized controlled trial · 5 results
Malouf-Sierra J · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017
Randomized controlled trial · 9 results
Cosman F · The Journal of clinical endocrinology and metabolism · 2010
Randomized controlled trial · 7 results
Bhandari M · Clinical orthopaedics and related research · 2016
Randomized controlled trial · 5 results
Orwoll ES · The Journal of clinical investigation · 2014
Randomized controlled trial · 10 results
Tsai JN · The lancet. Diabetes & endocrinology · 2019
Randomized controlled trial · 14 results
Aspenberg P · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010
Randomized controlled trial · 3 results
Dempster DW · The Journal of clinical endocrinology and metabolism · 2012
Randomized controlled trial · 4 results
Ledin H · Acta orthopaedica · 2017
Randomized controlled trial · 1 result
Tanavalee C · Scientific reports · 2025
Randomized controlled trial · 10 results
Finkelstein JS · JAMA · 1998
Randomized controlled trial · 11 results
Cohen A · The Journal of clinical endocrinology and metabolism · 2020
Randomized controlled trial · 10 results
Cosman F · The Journal of clinical endocrinology and metabolism · 2016
Randomized controlled trial · 2 results
Sim IW · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
Randomized controlled trial · 3 results
Winer KK · The Journal of clinical endocrinology and metabolism · 2003
Randomized controlled trial · 4 results
Cosman F · Bone · 2019
Randomized controlled trial · 18 results
Solomon DH · Arthritis & rheumatology (Hoboken, N.J.) · 2017
Randomized controlled trial · 6 results
Fazeli PK · The Journal of clinical endocrinology and metabolism · 2014
Randomized controlled trial · 7 results
Amorim T · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
Randomized controlled trial · 5 results
Rastogi A · Journal of diabetes · 2019
Randomized controlled trial · 4 results
Greenspan SL · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
Randomized controlled trial · 4 results
Winer KK · The Journal of clinical endocrinology and metabolism · 2010
Randomized controlled trial · 10 results
Cosman F · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011
Randomized controlled trial · 12 results
Hadji P · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
Randomized controlled trial · 10 results
Finkelstein JS · The Journal of clinical endocrinology and metabolism · 2006
Randomized controlled trial · 15 results
Walker MD · Endocrine · 2013
Randomized controlled trial · 13 results
Sethi BK · The Journal of the Association of Physicians of India · 2008
Randomized controlled trial · 9 results
Ganapathy A · Bone · 2023
Randomized controlled trial · 6 results
Park JH · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
Randomized controlled trial · 5 results
Genant HK · Current medical research and opinion · 2005
Randomized controlled trial · 5 results
Aspenberg P · The Journal of bone and joint surgery. American volume · 2016
Randomized controlled trial · 12 results
Glüer CC · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013
Randomized controlled trial · 7 results
Prasad TN · The Journal of clinical endocrinology and metabolism · 2026
Randomized controlled trial · 9 results
Miller PD · The Journal of clinical endocrinology and metabolism · 2007
Randomized controlled trial · 2 results
Chen P · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2006
Randomized controlled trial · 3 results
Lindsay R · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2009
Randomized controlled trial · 5 results
Harvey NC · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
Randomized controlled trial · 6 results
Dawson-Hughes B · The Journal of clinical endocrinology and metabolism · 2007
Randomized controlled trial · 10 results
Krege JH · Bone · 2012
Randomized controlled trial · 7 results
Lyritis G · Current medical research and opinion · 2010
Randomized controlled trial · 6 results
Uusi-Rasi K · Bone · 2005
Randomized controlled trial · 11 results
Li Y · Chinese medical journal · 2013
Randomized controlled trial · 13 results
Saag KG · Arthritis and rheumatism · 2009
Randomized controlled trial · 9 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 21 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA |
| 21 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Not listed as banned by WADA This check does not establish individual athlete eligibility. | 2026 List | wada-ama.org (opens in a new tab) |
209 safety results for Teriparatide (PTH 1-34).
Of seven participants who discontinued study drug because of repeated hypercalciuria, four were in the teriparatide groups and three in the placebo group.
Randomized controlled trialn = 2,074
1 more measurement in the study.
In Japanese patients with osteoporosis, adverse events were more frequent with teriparatide than placebo but generally mild and tolerable.
Randomized controlled trialn = 578
In patients with osteoporosis, adverse drug reactions were less frequent with twice-weekly than once-weekly teriparatide.
Randomized controlled trialn = 553
In postmenopausal women with osteoporosis, rhPTH and elcatonin were well tolerated.
Randomized controlled trialn = 453
In postmenopausal women with osteoporosis after bisphosphonates, nasopharyngitis was reported in fewer teriparatide than romosozumab recipients.
Randomized controlled trialn = 432
In glucocorticoid-induced osteoporosis, more teriparatide-treated patients had elevated serum calcium than alendronate-treated patients.
Randomized controlled trialn = 428
In glucocorticoid-induced osteoporosis, elevated predose calcium occurred in 21% with teriparatide versus 7% with alendronate.
Randomized controlled trialn = 428
In osteoporosis patients receiving either teriparatide regimen, no serious adverse events were reported.
Randomized controlled trialn = 359
The top 24 of 168 results.
The doses that these studies used. They are not recommendations.
56.5 μg once weeklyHuman
20 µg dailyHuman
28.2 μg twice weeklyHuman
20 microg once dailyHuman
20 μg once dailyHuman
20 microg/dayHuman
6 of 383 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ teriparatideEvidence summary for Teriparatide (PTH 1-34): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Bone and jointPharmacology | Human: 1,286 results from 263 studies: 678 increase, 240 decrease, 266 no significant change, 28 mixed, 74 not reported. Strongest design: Randomized controlled trial | Animal: 913 results from 131 studies: 584 increase, 120 decrease, 170 no significant change, 12 mixed, 27 not reported. Strongest design: Animal study (in vivo) | Lab: 26 results from 7 studies: 13 increase, 7 decrease, 6 no significant change. Strongest design: Ex vivo tissue | Computer model: 3 results from 1 study: 3 increase. Strongest design: In silico | 2,228 |
| Adverse eventsWhole body | Human: 137 results from 74 studies: 26 increase, 14 decrease, 32 no significant change, 65 not reported. Strongest design: Randomized controlled trial | Animal: 26 results from 9 studies: 10 increase, 2 no significant change, 14 not reported. Strongest design: Animal study (in vivo) | No results | No results | 163 |
| PainMusculoskeletal | Human: 62 results from 35 studies: 5 increase, 40 decrease, 17 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 62 |
| Electrolyte balanceKidney and urinary | Human: 30 results from 11 studies: 7 increase, 11 decrease, 4 no significant change, 1 mixed, 7 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 30 |
| PharmacokineticsPharmacology | Human: 27 results from 11 studies: 7 increase, 2 decrease, 8 no significant change, 10 not reported. Strongest design: Randomized controlled trial | Animal: 3 results from 3 studies: 2 increase, 1 not reported. Strongest design: Animal study (in vivo) | No results | No results | 30 |
| Kidney functionKidney and urinary | Human: 24 results from 11 studies: 7 increase, 7 decrease, 7 no significant change, 3 not reported. Strongest design: Randomized controlled trial | Animal: 3 results from 3 studies: 1 increase, 2 no significant change. Strongest design: Animal study (in vivo) | No results | No results | 27 |
| Exercise and physical functionMusculoskeletal | Human: 18 results from 15 studies: 6 increase, 6 decrease, 6 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 18 |
| Receptor activity and mechanismPharmacology | Human: 15 results from 5 studies: 7 increase, 4 decrease, 4 no significant change. Strongest design: Randomized controlled trial | Animal: 15 results from 7 studies: 5 increase, 4 decrease, 3 no significant change, 2 mixed, 1 not reported. Strongest design: Animal study (in vivo) | Lab: 16 results from 7 studies: 8 increase, 2 decrease, 1 no significant change, 4 mixed, 1 not reported. Strongest design: Ex vivo tissue | No results | 46 |
| Quality of lifeWhole body | Human: 13 results from 12 studies: 10 increase, 3 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 13 |
| Gastrointestinal adverse eventsPharmacology | Human: 12 results from 10 studies: 2 increase, 4 decrease, 1 no significant change, 5 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 12 |
| Hormone levelsEndocrine and hormones | Human: 6 results from 1 study: 3 increase, 2 decrease, 1 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 6 |
| Treatment adherence and retentionWhole body | Human: 6 results from 4 studies: 6 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 6 |
12 outcome groups shown of 36 · 2,709 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
25 registered trials loaded of 168, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status. The counts cover only the loaded trials.